MACROGENICS INC. - CO

MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)

22 Mar 2023 12:22:37 By Nasdaq GlobeNewswire

MacroGenics Provides Corporate Update and 2022 Financial Results

15 Mar 2023 15:01:35 By Nasdaq GlobeNewswire

MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million

08 Mar 2023 16:36:43 By Nasdaq GlobeNewswire

MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call

07 Mar 2023 17:00:00 By Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conferences

02 Mar 2023 15:30:00 By Nasdaq GlobeNewswire

MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium

13 Feb 2023 16:20:00 By Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conferences

06 Feb 2023 15:30:00 By Nasdaq GlobeNewswire

MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 16:50:00 By Nasdaq GlobeNewswire

MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

04 Jan 2023 15:30:00 By Nasdaq GlobeNewswire

MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab

17 Nov 2022 17:10:00 By Nasdaq GlobeNewswire

MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results

03 Nov 2022 15:01:01 By Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conferences

02 Nov 2022 15:30:00 By Nasdaq GlobeNewswire

MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call

26 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conferences

02 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results

08 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call

25 Jul 2022 15:01:00 By Nasdaq GlobeNewswire

MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer

08 Jul 2022 15:30:00 By Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conference

08 Jun 2022 15:01:00 By Nasdaq GlobeNewswire

MacroGenics Announces Appointment of William Heiden to Board of Directors

23 May 2022 15:01:00 By Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conference

17 May 2022 15:01:00 By Nasdaq GlobeNewswire